Ficolin-2 triggers antitumor and anti-pathogen effects by activating antigen presenting cells and CD8+T cells

Quanquan Ding, Min Liu, Xiao-Lian Zhang*
State Key Laboratory of Virology and Medical Research Institute, Hubei Province Key Laboratory of Allergy and Immunology and Department of Immunology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, P. R. China.

ABSTRACT

Ficolins are important serum complement lectins with subunits consisting of both collagen-like long thin stretches and fibrinogen-like globular domains with lectin activity usually binding N-acetylglucosamine (GlcNAc). Like collectins such as mannan-binding lectin, ficolins are secreted lectin-type pattern recognition receptors, and activate the lectin pathway of complement activation. Three human ficolins, namely, L-ficolin/P35 (FCN-2/ficolin-2), M-ficolin (FCN-1/ficolin-1), and H-ficolin/Hakata antigen (FCN-3/ficolin-3), and two mouse ficolins (ficolins-A and -B) have been identified. Ficolin-2 is closely related to human ficolin-2. They are mainly synthesized in the liver and then secreted into blood circulation.

Ficolin-2 binds tumor cells, macrophages and CD8+ T cells in vitro

A recent report showed that ficolin-3 directly attacked cancer cells via a novel complement pathway. Lower ficolin-2 protein expression was found in the tissue samples of Hepatocellular Carcinoma (HCC) patients with HCC metastasis compared to non-metastasis patients. Despite this, little is known about ficolin-2’s functions during malignancy. Recently, Prof. Zhang’s research group reported that ficolin-2 could trigger antitumor effect by activating macrophages and CD8+ T cells in which they revealed the immune roles of serum ficolin-2 in association with immune cells in several
important cancers, including colon cancer, lung cancer and hepatocarcinoma.

In this work, tumor cells and immune cells were incubated with different concentrations of recombinant ficolin-2 protein and the binding abilities were detected by flow cytometry (FCM) analysis. Firstly, Ding et al found that ficolin-2 protein could bind to CT26 colon carcinoma cells and Lewis lung carcinoma cells, macrophages, dendritic cells (DCs) and CD8+ T cells, but failed to bind to CD4+ T cells, in vitro in a dose-dependent manner. Both GlcNAc and Mannan, especially GlcNAc, competitively blocked their binding. Among all tested cell types, ficolin-2 bound to macrophages best and the fibrinogen like domain might be the main region governing the binding of ficolin-2 to macrophages.

The serum ficolin-2 concentrations in 346 cancer patients and 143 healthy donors were detected by enzyme-linked immuno sorbent assay (ELISA)14. Much lower levels of serum ficolin-2 were observed in cancer patients compared to healthy donors, these data suggest that low levels of serum ficolin-2 may be related to malignancy.

**Ficolin-2 triggers antitumor effect in vivo by activating antigen presenting cells and then CD8+ T cells**

Ding et al further determined the roles of ficolin-2/A in the development of tumors in vivo, and observed that significant inhibition of CT26 tumor development in ficolin-2 and ficolin-A-treated mice compared to empty vector treated mice. Similarly, ficolin-2 and ficolin-A treatment also led to a blunted growth of Lewis tumor cells compared to empty vector treated mice. All these data strongly demonstrated that ficolin-2 and ficolin-A could remarkably inhibit tumor cells growth in vivo.

Further, nude mice were insensitive to treatment with the ficolin-2/ficolin-A expression plasmids, which suggest that T cells are involved in the antitumor effects triggered by ficolin-2. When early antigen-processing cells (APCs) and CD8+ T cells were depleted, mice exhibited no significant differences in tumor growth between the ficolin-2-treated group and non-ficolin-2-treated group. Ficolin-2 still exhibited antitumor effects when CD4+ T cells and late-stage APCs were depleted. These data suggest that early-stage APCs and CD8+ T cells are essential for ficolin-2 to exert antitumor functions in vivo. In addition, both ficolin-2 and ficolin-A treatments facilitated the recruitment of inducible nitric oxide synthase (iNOS) M1 macrophages (iNOS+F4/80+) and CD3+CD8+ T cells to tumor sites.

Further research showed that ficolin-2 tilted the balance from M0 or M2 macrophages to M1 macrophages and enhanced macrophage M1-biased polarization response in vitro14. Ficolin-2 also enhanced secretion of inflammatory cytokines interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), interferon-gamma (IFN-γ), IL-17A IL-22 and nitric oxide (NO) from macrophages in vitro. Transwell experiments showed that IL-6 and TNF-α released from macrophages stimulated by ficolin-2 played major roles in ficolin-2’s antitumor effects.

Ficolin-2 can’t activate CD8+ T cells directly14. However, mixed lymphocytes reaction (MLR) experiments showed that ficolin-2-activated APCs (macrophages and DCs) enhanced the expression of CD107a, intracellular granzyme B (GrB)/perforin and Ki67 of CD8+ T cells and facilitated enhanced antigen-specific cytotoxicity and proliferation of CD8+ T cells. Further, significantly increased expressions of surface CD80, CD86, MHC II and intracellular IL-12 of DCs were observed after the stimulation of ficolin-2. These results suggest that ficolin-2 promotes the maturation of DCs and then activates CD8+ T cells.

**Ficolin-2 exerts antitumor effects depending on Toll-like receptor (TLR) 4 of macrophage**

TLR4 was demonstrated to be a receptor of ficolin-214. Flow cytometry analysis showed that ficolin-2 bound to TLR4+ macrophages/DCs in a dose-dependent manner, and the binding ability was much higher than that for TLR4-/- macrophages/DCs. Anti-TLR4 and anti-ficolin-2 antibodies significantly blocked the binding of ficolin-2 to TLR4+ macrophages. Physical associations between ficolin-2 and TLR4 were determined by GST-pull down assay. CD80, CD86, MHC II and IL-12 expression levels in ficolin-2-treated TLR4+/+ DCs were significantly higher than those in ficolin-2-treated TLR4-/- DCs. These results suggest that ficolin-2 promotes the maturation and the antigen presenting ability of DCs via TLR4. And Ficolin-2 induced macrophage activation and M1 polarization response also depended on TLR4, because a significant impairment in the mRNA expressions of inflammatory cytokines IL-6, TNF-α and IFN-γ, especially TNF-α were observed in the TLR4-/– macrophages compared to those in the TLR4+/- macrophages. The mRNA levels of chemokine ligand (CCL) CCL4 and CCL5 of macrophages, especially CCL5, were also impaired by the deficiency of TLR4 after the stimulation of ficolin-2. Additionally, the mRNA levels of IL-1β, IL-12p40 and iNOS in ficolin-2-treated TLR4+/+ bone marrow derived M0 macrophage (M0-BMDM) or M2-BMDM were significantly lower than those in ficolin-2-treated TLR4+/+ group. Transforming growth factor (TGF)-β and arginase 1 (Arg-1) mRNA levels in ficolin-2-treated TLR4+/+ M2-BMDM were also higher than those in ficolin-2-treated TLR4+/+ M2-BMDM. Ficolin-2 induces M1 polarization response dependent on TLR4.

Ficolin-2 exerts antitumor effects depending on TLR4 of macrophage in vivo. The Hca-f tumor sizes in TLR4+/+ mice were significantly smaller than those in TLR4-/- mice at different time course. The Hca-f mouse liver tumor sizes...
in the empty vector treated TLR4+/+ mice group were the biggest compared to those in ficolin-2 treated-TLR4+/+ / TLR4−/− mice. These data strongly demonstrate that ficolin-2 significantly inhibit multiple mouse tumor cells growth in different background mice, and TLR4 is involved in macrophage-mediated antitumor effect exerted by ficolin-2.

A putative model of immune-mediated anti-tumor effect by ficolin-2 was proposed (Figure 1). The model shows that ficolin-2 binds to TLR4 of macrophage and DCs, induces early macrophages to release proinflammatory cytokines (e.g., TNF-α and IL-6), chemokines (CCL5) and NO; activates M1 macrophage (iNOS+) polarization; enhances the ability of APCs (macrophage and DCs) to present antigens to CD8+ T cells; and then enhances antigen-specific CD8+ T cell activation and subsequently protects against tumor progression in vivo. In addition, ficolin-2 acts as a link between tumor cells and immune cells.

Taken together, these new findings may contribute to the development of ficolin-2 as a novel immunotherapeutic agent that can prevent several important diseases including cancers and infectious diseases.

Acknowledgements

This work was supported by grants from the National Grand Program on Key Infectious Disease of China (2017ZX10201301), the National Natural Science Foundation of China (31370197, 21572173, 81501377, 81471910, and 91740120), Natural Science Foundation Project and Technological Innovation Major Project of Hubei Province (2016CFA062, 2016ACA150), the Hubei Province’s Outstanding Medical Academic Leader Program (523-276003), the Science and Technology Program of Wuhan (201150530141) and the Wuhan Applied Basic Research Project (2015060101010030).

References

9. Chen T, Hu Y, Ding Q, et al. Serum ficolin-2 concentrations are


